Firazyr Lowers Attack Duration, But Increases Healthcare Costs in Angioedema Patients
Patients with hereditary angioedema caused by deficiencies in the complement C1-inhibitor protein experience symptomatic relief and remission with the use of on-demand treatments, according to an Italian study. Firazyr (icatibant), an agonist of the bradykinin receptor, led to reduced attack durations compared to plasma derived C1-inhibitor treatments. But the treatment also…